Quarterly report pursuant to Section 13 or 15(d)

Revenue (Tables)

v3.22.1
Revenue (Tables)
3 Months Ended
Mar. 31, 2022
Revenue from Contract with Customer [Abstract]  
Schedule of Recognized Revenues From Strategic Partnerships and Other License Agreements
The Company recognized revenue from the following strategic partnerships and other license agreements (in thousands):
  Three Months Ended March 31,
  2022 2021
Seagen $ 312  $ 366 
AstraZeneca 4,753  14,500 
Servier 4,734  767 
Genentech 1,189  — 
Total Revenue $ 10,988  $ 15,633 
Schedule of Potential Milestone Payments
Under the Company’s existing strategic partnerships and other license agreements, the Company could receive the following potential milestone payments (in millions):
  Research, Development, Regulatory & Commercial Milestones Sales Milestones
AstraZeneca $ 900  $ 4,100 
Servier 133  100 
Seagen 754  450 
Boston Pharmaceuticals 88  265 
Genentech 844  600 
Total potential milestone payments $ 2,719  $ 5,515